Financial reports
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
27 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
25 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Mar 24
8-K
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
22 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Sep 23
8-K
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
10 Aug 23
8-K
Other Events
12 Jul 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Salarius Pharmaceuticals Announces $6 Million Private Placement
16 May 23
8-K
Other Events
13 Mar 23
8-K
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
10 Jan 23
8-K
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
1 Dec 22
Registration and prospectus
424B3
Prospectus supplement
7 Jun 23
S-3/A
Shelf registration (amended)
1 Jun 23
S-3
Shelf registration
26 May 23
D
$6.00 mm in equity / options / securities to be acquired, sold $6.00 mm, 1 investor
25 May 23
S-8
Registration of securities for employees
15 Feb 23
S-3
Shelf registration
5 Aug 22
S-3
Shelf registration
10 Jun 22
D
$2.33M in options / securities to be acquired, sold $2.33M, 4 investors
5 May 22
424B5
Prospectus supplement for primary offering
25 Apr 22
S-8
Registration of securities for employees
22 Feb 22
Proxies
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEF 14A
Definitive proxy
26 Mar 24
DFAN14A
Additional proxy materials by non-management
19 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
12 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
Other
EFFECT
Notice of effectiveness
8 Jun 23
CORRESP
Correspondence with SEC
2 Jun 23
UPLOAD
Letter from SEC
1 Jun 23
EFFECT
Notice of effectiveness
17 Aug 22
CORRESP
Correspondence with SEC
12 Aug 22
UPLOAD
Letter from SEC
10 Aug 22
EFFECT
Notice of effectiveness
24 Jun 22
CORRESP
Correspondence with SEC
21 Jun 22
UPLOAD
Letter from SEC
21 Jun 22
UPLOAD
Letter from SEC
9 May 22
Ownership
4
David J. Arthur
12 Apr 24
4
Mark J Rosenblum
22 Feb 24
4
William K. McVicar
22 Feb 24
4
Bruce J Jr. McCreedy
22 Feb 24
4
Jonathan I Lieber
22 Feb 24
4
Paul Lammers
22 Feb 24
4
Tess Burleson
22 Feb 24
4
ARNOLD C HANISH
22 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D
Lee Elvin Sanghwan
27 Oct 23